Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis Exforge Group (amlodipine/valsartan by Year
Exforge Group (amlodipine/valsartan — hypertension) ($M)
Novartis Exforge Group (amlodipine/valsartan: $727M in FY2025, up 3.4% from a year earlier.
Latest, FY2025
727
Period ended Dec 31, 2025
Change on a year earlier
+3.4%
703 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Exforge Group | 727 | 703 | 3 | 4”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Exforge Group (amlodipine/valsartan — hypertension) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 727 | +3.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 703 | -1.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 713 | -4.0% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 743 | -17.5% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 901 | -8.1% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 980 | -4.4% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 1,025 | +2.3% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 1,002 | +4.4% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 960 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up exforge Group (amlodipine/valsartan
Cite this data
StockData. (2026). Novartis Exforge Group (amlodipine/valsartan ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-exforge-group
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.